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Abstract
Background: The threat of recurring influenza pandemics caused by new viral strains and the occurrence of escape 
mutants necessitate the search for potent therapeutic targets. The dependence of viruses on cellular factors provides a 
weak-spot in the viral multiplication strategy and a means to interfere with viral multiplication.
Results: Using a motif-based search strategy for antiviral targets we identified caveolin-1 (Cav-1) as a putative cellular 
interaction partner of human influenza A viruses, including the pandemic influenza A virus (H1N1) strains of swine 
origin circulating from spring 2009 on. The influence of Cav-1 on human influenza A/PR/8/34 (H1N1) virus replication 
was determined in inhibition and competition experiments. RNAi-mediated Cav-1 knock-down as well as transfection 
of a dominant-negative Cav-1 mutant results in a decrease in virus titre in infected Madin-Darby canine kidney cells 
(MDCK), a cell line commonly used in basic influenza research as well as in virus vaccine production. To understand the 
molecular basis of the phenomenon we focussed on the putative caveolin-1 binding domain (CBD) located in the 
lumenal, juxtamembranal portion of the M2 matrix protein which has been identified in the motif-based search. Pull-
down assays and co-immunoprecipitation experiments showed that caveolin-1 binds to M2. The data suggest, that 
Cav-1 modulates influenza virus A replication presumably based on M2/Cav-1 interaction.
Conclusion: As Cav-1 is involved in the human influenza A virus life cycle, the multifunctional protein and its 
interaction with M2 protein of human influenza A viruses represent a promising starting point for the search for 
antiviral agents.
Background
In the last few years the interaction of viral matrix pro-
teins or precursors with cellular proteins has attracted
much attention in the field of medical virology due to the
increase in the understanding of their interplay in late
viral processes like protein transport, virus assembly and
budding. Viral matrix proteins establish the link between
outer shell and capsid core of enveloped viruses and bring
together these parts in the virus assembly step. Moreover,
matrix proteins frequently determine the place where the
assembly step occurs. In influenza A viruses two M pro-
teins are located on RNA7 of the negative-stranded, seg-
mented RNA virus. The M1 protein functions as a typical
matrix protein, while M2 exerts multiple tasks in the
early and late phase of virus infection. M2 tetramers form
an ion channel and in the early phase of virus infection
M2 serves for the release of viral nucleocapsid by acidifi-
cation of endosomes. In the late phases, M2 prevents pre-
mature activation of newly synthesized HA [1] and -in
concert with M1- contributes to virus budding and mor-
phology. The involvement in virus exit has been assigned
to the cytoplasmic tail of the protein [2-4]. Influenza
viruses bud from lipid rafts and for this event the compo-
nents of the viral envelope (haemagglutin HA, neuramin-
idase NA, M2) and the RNA containing protein complex
(vRNP) must come together to form infectious virus [5-
7]. Interestingly, the endosomal sorting machinery
(ESCRT), which has been involved in late steps of other
viruses, does not contribute to influenza virus budding
[6,8]. Accordingly, other routes and gates have been sug-
gested for the transport of influenza proteins and virus
assembly/budding [5].
In several previous investigations caveolin-1 (Cav-1), a
multifunctional, raft-resident membrane protein has
been linked to the virus replication of retroviruses HIV-1
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and amphotropic mouse leukemia virus, rotavirus and
respiratory syncytial virus [9-13]. Interestingly, a contri-
bution of Cav-1 to HA transport has been reported for
influenza virus infected MDCK cells [14]. In a recent
investigation of the enveloped γ-retroviruses budding
from lipid rafts we showed that caveolin-1 (Cav-1) inter-
acts specifically with the MLV retroviral matrix protein in
the Gag precursor, suggesting that Cav-1 serves in posi-
tioning the Gag precursor at lipid rafts [13]. Not surpris-
ingly, Cav-1 is incorporated into MLV virions released
from mouse NIH3T3 [13,15]. Subsequently, competition
and inhibition experiments provided evidence that Cav-1
modulates MLV retrovirus production [13]. Taken
together, these findings pointed to a general contribution
of Cav-1 in virus replication strategy and opened the pos-
sibility that other virus families budding from lipid rafts
may co-opt the functions of Cav-1. In our search for cel-
lular/viral targets a database screen for Cav-1 binding
sites notably revealed that structural proteins like matrix
proteins of other viral families, e.g. Orthomyxoviridae
with influenza A virus as a representative, exhibit regions
of homology with a consensus motif for Cav-1 binding
(Cav-1 binding domain, CBD) (Wirth, M, unpublished).
To address the biological relevance of the interplay of
Cav-1 with influenza proteins we performed inhibition
experiments with a dominant-negative Cav-1 mutant,
k n o c k - d o w n  b y  C a v - 1  R N A i  a s  w e l l  a s  c o m p e t i t i o n
experiments with M2 fusion proteins. We found, that the
yield of human influenza virus progeny is affected by the
presence/absence of Cav-1. The data suggest that Cav-1
can support the human influenza virus A life cycle. Pull-
down and co-immunoprecipitation experiments were
performed which showed binding of M2 and Cav-1.
Results
Influenza A virus titres are affected in MDCK Cav-1 knock-
down cells
We used MDCK (ATCC CCL-34), a canine kidney cell
line commonly used in basic influenza virus research and
vaccine production [16-19]. To elucidate the biological
importance of Cav-1 in the influenza life cycle, MDCK
cells were infected with a selectable retroviral Cav-1
RNAi vector carrying a puromycin-resistance gene
(RVH1-Puro-Cav-1) as well as control RVH1-Puro alone
[20]. We found that the Cav-1 content decreased gradu-
ally to 25% of the value in wild-type MDCK at 14-17 days
post infection (d.p.i.) (data not shown). Next, Cav-
1RNAi-MDCK cells exhibiting the lowest Cav-1 levels
(day 17 p.i.), wt-MDCK or RVH1Puro-MDCK were cho-
sen for infection experiments with influenza A virus (Fig.
1). A high m.o.i. of 10 was used to challenge the host sys-
tem, as residual Cav-1 in knock-down cells may suffice to
support influenza virus production upon infection at low
m.o.i. Maximum titres of 4.5 × 107 pfu/ml were achieved
from wild-type cells in a plaque assay . Strikingly , titres
from Cav-1 knock-down MDCK cells were decreased up
to to 32% of wild-type level. The infection experiments
were repeated at different days post RNAi transfer (12,
15, 20 d.p.i) and with different m.o.i. (0.1, 1, 10). Notably,
the experiments revealed similar results with an average
decrease of influenza titres to 57.3% of wild-type levels
(Fig. 1). The statistical analysis of nine independent
experiments revealed that the 1.5-3 fold reduction in
titres observed is highly significant (paired t-test, >99%
confidence, p > 0,01) When cells stably transduced with
control virus vector devoid of Cav-1 interfering
sequences (RVH1puro) were infected with influenza A
virus (m.o.i. = 10) titres of released virus was affected
only marginally. Thus, we conclude that Cav-1 reduction
in MDCK is correlated with a decrease in influenza virus
progeny. This suggests, that Cav-1 directly or indirectly
affects the human influenza virus life cycle in MDCK
cells.
A dominant-negative Cav-1 mutant decreases influenza A 
virus titres in MDCK cells
A dominant-negative Cav-1 mutant has been described
which functionally inactivates caveolin-1 upon binding
[21]. The mutant carries a F92A/V94A double mutation
in the scaffolding domain (SD) of canine caveolin-1.
Expression in rat adipose and COS-1 cells has been
shown to interfere with the interaction of Cav-1 with the
insulin receptor and impairs receptor function.
To confirm our results from knock-down experiments,
we investigated the effect of expression of the dominant-
negative SD mutant and over-expression of wild-type
caveolin-1 on virus production. Expression efficiency
Figure 1 Inhibition of influenza A/PR/8/34 multiplication in 
MDCK Cav-1 knock-down cells. Titres of A/PR8 infected MDCK Cav-1 
knock-down cells at day 13-17 after RNAi vector treatment and infec-
tion with influenza A/PR/8/34. Standard errors are depicted. Analysis 
using a paired t-test (n = 9) revealed that the 1,5 to 3 fold reduction in 
titres compared to MDCK control cells is statistically highly significant 
(p > 0.001).
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could be monitored easily, as endogenous and trans-
fected, recombinant caveolins differ in their mobility in
SDS-PAGE due to a C-terminal myc-tag (Fig. 2 bottom).
Cav-1 appeared in two isoforms, with molecular weights
of 21 and 24 kD, respectively [22,23]. Expression efficien-
cies ranged from 7-29% (SD) and 20-50% (wt-Cav-1) with
respect to endogenous Cav-1 level. Provided that the
myc-tag does not interfere with Cav-1 antibody detection
and assuming a 1:1 interaction of SD mutant and endoge-
nous Cav-1, sufficient competitor amounts should be
available in successfully transfected cells. Next, tran-
siently transfected MDCK and mock-transfected MDCK
cells were infected with influenza A/PR/8/34 virus one
day after transfection. 24 h later supernatants were used
for titre determination (Fig. 2 top). To account for
between-session-variations in cell culture, values were
normalized to virus production from infected wt MDCK
(100%). To exclude sensitivity of influenza infection to the
actual transfection process, pEGFP-N1 transfected con-
trol cells were infected with PR8 virus in a control experi-
ment. Strikingly, SD mutant expression in MDCK cells
interfered with human influenza A virus replication and
decreased the viral titres on average 1.6 fold to 62% of
titres from wild-type MDCK (average of three indepen-
dent experiments, standard deviation = ± 15,95). Com-
pared to processed EGFP control cells, virus yield from
Cav-1 wt- or SD-transfected MDCK cells was reduced
considerably, which excludes that effects observed on
virus production are derived from the transfection pro-
cess (data not shown). This strongly suggests that inter-
ference with Cav-1 function in MDCK cells interferes
with human influenza A virus replication. Interestingly,
over-expression of wild-type Cav-1 also diminished influ-
enza virus production, since viral titres reached only 56%
± 10.53 compared to non-treated MDCK (n = 3). Thus,
surplus exogenous Cav-1 interferes with endogenous
Cav-1 function, too. However, compared to the SD
mutant twice the amount of Cav-1 wt is necessary to
account for a comparable level of inhibition, as judged by
Western Blot analysis.
Competition with an influenza virus structural protein 
decreases influenza A virus production in MDCK cells
Search for putative Cav-1 interaction partners
In order to elucidate the molecular basis of the interac-
tion we scanned influenza A virus proteins for putative
binding motifs. Cav-1 binds to various cellular proteins
like membrane receptors, soluble or membrane-associ-
ated molecules [24] as well as several viral proteins and
exerts functions in localisation, transport and cellular sig-
nalling (Table 1). Signalling is preceded by phosphoryla-
tion of Cav-1, which initiates events leading either to
activation of specific signalling pathways [21] or mainte-
nance of signalling-competent, yet inactive complexes
[24]. A specific, lumenal domain termed caveolin scaf-
folding domain (CSD, aa 82-101) which resides adjacent
to the region of membrane insertion, is responsible for
specific protein binding in the vast majority of cases
[24,25]. Two consensus sequences have been identified in
phage-display experiments and in the primary structure
of Cav-1 binding partners which were termed caveolin
binding domains (CBD) [26]. CBDs have been recognized
in cellular [24] and viral proteins (Table 1). The consensus
sequence comprises a run of 3 aromatic residues (W, F, Y)
separated by a characteristic spacing (ΦxxxxΦxxΦ;
ΦxΦxxxxΦ; where x stands for any amino acid and Φ for
W, F, Y). Our screening for CBDs identified putative
binding regions in HA, PB2 and M2 of influenza A virus.
Especially, a region in the M2 channel protein turned out
to be highly conserved among human influenza A viruses
(Fig. 3B). The putative CBD overlaps with a loop/helical
domain immediately following the M2 transmembrane
region at the lumenal site of M2 (Fig. 3A). The CBD sur-
rounds Cys 50, which is palmitoylated and faces the
membrane allowing for insertion of the palmitoyl residue
into the lipid bilayer. Thus, the CBD would be located
favourably for interaction with the Cav-1 scaffolding
domain [27,28]. Strikingly, compared to M2 of A/PR8/34
as a reference the CDB core motif (positions F47, Y52,
F55) and immediately adjacent amino acid residues are
Figure 2 Inhibition of influenza A/PR/8/34 multiplication in 
MDCK cells by means of a dominant-negative Cav-1 mutant. Top: 
Relative titres of MDCK cells expressing myc-tagged dominant-nega-
tive caveolin-1 (SD), wild-type (wt) Cav-1 cDNA or mock-transfected 
cells (Ctrl) 24 h after infection with influenza A/PR8 (m.o.i. = 1) and nor-
malisation to wt MDCK infection (100%). Results of three independent 
experiments are shown. Bottom: Immunodetection of endogenous, 
myc-tagged wild-type (wt) and mutant caveolin-1 (SD) in transfected 
MDCK. Relative protein levels are indicated (endogeneous Cav-1 = 
100%). Cav-1 appears in the two known isoforms (Cav-1α 24 kDa; Cav-
1β 21 kDa), the β-isoform is missing 31 aminoterminal residues of the 
Cav-1 protein.
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completely conserved in 8 M2 sequences available for the
pandemic influenza virus of swine origin A/2009 (H1N1)
(Fig. 3C). Furthermore, motif conservation is observed in
a former H1N1 strain appearing in 1977, but homology is
restricted to the aromatic core and to a lesser extent to
adjacent residues. Surprisingly, in M2 of influenza A/
1918 the CBD motif is not conserved, as its third aro-
matic residue phenylalanine is changed to leucine, a resi-
due commonly found in the M2 of avian influenza A
viruses at that position (G.-V. Hemgård and M. Wirth,
unpublished observation).
Competition of Cav-1 binding with M2 affects production of 
influenza A/PR/8/34
These hints prompted us to investigate the effect of M2
over-expression on the influenza A virus life cycle in
MDCK cells. We hypothesized, that surplus M2 fusion
protein may reduce the concentration of available, func-
tional Cav-1 by complexing. To monitor M2 protein lev-
els and localization we generated mammalian expression
vectors containing cDNAs for fusion proteins of M2 (A/
PR/8/34) with desRedExpress, a red fluorescent, tetra-
meric protein (pM2PR8DsRed) or EGFP (enhanced green
fluorescent protein) (pM2PR8_EGFP) and transfected
purified DNA into MDCK cells. Expression levels and
localization of the fluorescent proteins were followed 1
and 2d after transfection. The transfection efficiency
(ratio of fluorescent/nonfluorescent cells) ranged
between 10 and 15%. M2 fluorescent fusion proteins ini-
tially were found in the cytoplasma and started to localize
at the plasma membrane at day 1 post transfection. As
expected M2DsRed and M2EGFP localization did not
differ from localization of M2 after infection with A/PR8/
Figure 3 Schematic representation of M2 domains and conservation of a putative caveolin-1 binding domain in human influenza A viruses. 
A. For reasons of clearness, only a M2 monomer is indicated in the drawing. M2 tetramers function as an ion-pump (residing in a helical domain in the 
transmembrane region represented by cylinder 1). The C-terminal region is important for virus assembly and budding. A palmitoyl residue (jigsaw 
line) is linked to cysteine 50. The caveolin-1 binding domain resides in the loop and helical domain (cylinder 2) tilted perpendicularly with respect to 
the TM domain and is supposed to face the inner leaflet of the membrane. B. Conservation of a putative caveolin-1 binding domain. The core motif 
of the caveolin-1 binding domain (bold letters F47, Y52, F55) is highly conserved among most subtypes of human influenza A viruses (insert). C. Align-
ment of M2 (H1N1) sequences. The putative CBD core (bold) and adjacent sequences of influenza A viruses of pandemic H1N1 strains (2009 USA/
Mexico, 1977 'Russian flu', 1918 'Spanish flu') were aligned to the M2 region (aa 41-65) of the Puerto Rico strain 8/1934. Conserved residues: asterisks 
*. Amino acid deviations: faint red.
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Table 1: Cav-1 interactions with viral proteins
Virus family
(-viridae)
Virus Protein Protein function Type of 
interaction with 
protein partner
Type of 
interaction with 
Cav-1
Reference
Retro HIV-1 gp41 Transmembrane, 
fusion
Binding to CBD in 
HIV-1, but not HIV-
2 or SIV
Binding to CSD* (Benferhat et al., 
2008; 
Hovanessian et al., 
2004)
HIV-1 gp41 Transmembrane, 
fusion
Binding to six-
helix bundle
Binding to CSD (Huang et al., 
2007)
HIV-1 Not known Not known Cav-1 membrane 
insertion domain
(Llano et al., 2002)
MLV-
amphotropic, 
ecotropic
MA-Gag Matrix, associates with 
membranes, link 
between capsid, 
plasma membrane, 
and viral membrane 
proteins
Binding mediated 
by a CBD in MA, 
interaction 
locates MA to lipid 
rafts domains in 
PM
Interaction with 
CSD*†
(Beer and Wirth, 
2004; Yu et al., 
2006)
Corona SARS ORF3a Not known, 
Functioning in Golgi 
localization?
Binding to several 
CBDs
Not known, 
interaction with 
CSD likely
(Padhan et al., 
2007)
Orthomyxo Influenza A virus 
human
M2 Early phase: Ion 
channel, viroporin
Late Phase: matrix, 
virus assembly and 
budding
Binding. Protein 
regions 
presumably CBD 
aa47-55
Binding to CSD*†
Binding to CSD‡
This investigation
Zou et al. 2009
Influenza A virus 
human
HA Receptor binding Colocalization in perinuclear regions (Scheiffele et al., 
1998)
Paramyxo RSV ? ? Colocalization 
with internal viral 
filaments, 
colocalization at 
lipid rafts
Binding not 
specified, 
redistribution of 
Cav-1 after 
phosphorylation
(Brown et al., 
2002; Brown, 
Rixon, and 
Sugrue, 2002; 
McDonald et al., 
2004)
Reo Rotavirus NSP4 Ion channel formation, 
ER and caveolae 
localization, important 
for morphogenesis
Binding aa114-
135 (enterotoxic 
peptide) 
amphipatic helix 
at the C-terminus
Binding and 
colocalization, 2 
independent 
binding sites at 
the N-terminus 
(aa2-22)and C-
terminus (aa161-
178) identified, 
influence on 
localization or 
transport?
(Mir et al., 2007; 
Parr et al., 2006; 
Storey et al., 2007)
*Pull-down experiments with biotinylated CBD-peptides
†Co-immunoprecipitation
‡ ELISASun et al. Virology Journal 2010, 7:108
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34, except that upon over-expression M2 fusion proteins
partially stacked in juxtanuclear regions (data not
shown). Next, we carried out mixed transfection/infec-
tion experiments. For that purpose M2dsREd, M2EGFP
and mock-transfected MDCK cells were infected with
influenza A/PR/8/34 one day after transfection. 24 h later
supernatants were collected and processed for titre deter-
mination (Fig. 4). Interestingly, M2 expression in infected
MDCK decreased viral titres to 40% (M2DsRed) and 85%
of (M2EGFP) of the level of non-transfected cells. Thus,
M2 over-expression interferes with human influenza
virus propagation, presumably by competing with endo-
geneous M2 for Cav-1 interaction.
The M2 matrix protein of human influenza A interacts with 
Cav-1
To verify the predicted M2/Cav-1 binding, pull-down as
well as co-immunoprecipitation experiments were car-
ried out. For pull-down experiments, biotinylated pep-
tides carrying the putative CBD of M2 or a mutant CBD
with alanines instead of the motif's core aromatic resi-
dues were incubated with cell lysates and complexes were
processed as specified in Material and Methods (Fig. 5A).
Results from two independent experiments show that the
M2 CBD-peptide indeed pulls down caveolin-1, while the
alanine-CBD mutant exhibits a strongly reduced ten-
dency to interact with Cav-1. These results indicate that
M2 of influenza A/PR/8/34 indeed exhibits at least one
caveolin-binding domain.
To confirm data of the pull-down experiments, co-
immunoprecipitation experiments were performed using
NIH3T3 or MDCK cells after transfection of pEP24c, an
expression vector containing M2 PR/8 [29] or a vector
harbouring fusion protein of M2 with fluorescent marker
EGFP. 24 h later cell lysates were prepared in the presence
of octylglucoside, a detergent that disrupt lipid rafts, as
described previously [13]. In the first series of experi-
ments, polyclonal anti-Cav-1 antibodies were used to
pull-down Cav-1 complexes from lysates. Precipitated
complexes were probed for the presence of M2 after
Western Blot and immunostaining. In these experiments,
the Cav-1 antibodies clearly pulled down a complex that
contained a M2 from pEP24c transfected MDCK cells
(Fig. 5B, a) or the M2 fusion protein from pM2PR8-EGFP
transfected MDCK or NIH3T3 cells (Fig. 5B, b) as well as
infected MDCK cells (Fig. 5B, c left panel). In the second
experimental setting, vice versa, monoclonal anti-EGFP
antibodies were used to precipitate M2 binding partners
and a rabbit anti-Cav-1 antibody was used to probe for
the presence of caveolin (Fig 5B, c right panel). These
types of experimental settings identified M2 complexed
with Cav-1 and vice versa in both cell lines, NIH3T3 and
MDCK. Thus, the results suggest that M2 has the capa-
bility to interact directly or indirectly with caveolin-1 in
different cell lines. With respect to the type of interaction,
i t  i s  n o t a b l e ,  t h a t  c a v e o l i n - 1  a s  w e l l  a s  M 2  h a v e  b e e n
reported to bind cholesterol via cholesterol specific rec-
ognition domains [30,31]. This prompted us to investi-
gate, whether cholesterol is involved in the M2/caveolin-
1 interaction. For that purpose methyl-β-cyclodextrin
(MβCD) was used to deplete cell lysates from cholesterol
before co-immunoprecipatation (Fig. 5B b and 5c). Inter-
estingly, in pM2PR8-EGFP transfected NIH3T3 cells as
well as in PR8 virus-infected MDCK cells, signals from
co-immunoprecipated proteins decreased to a certain
extent, if cholesterol was removed from the lysate before
pull-down. These findings imply, that cholesterol seems
to support the interaction of M2 with caveolin-1.
Discussion
Viruses recruit the cellular machinery to support their
own multiplication and elicit an early host response to
overcome the unwanted viral invaders. In our contribu-
tion we investigated the ability of caveolin-1, a multifunc-
tional protein, to interact with components in the
influenza A virus life cycle and to interfere with influenza
A virus production. Cav-1 represents an organizing ele-
ment at the plasma membrane and serves on localization
and accumulation of proteins in lipid rafts and transmis-
sion of signalling events [24]. Furthermore, the protein
contributes to intracellular cholesterol transport and has
been identified as the main determinant of caveolae,
invaginations of the plasma membrane used for entry of
molecules and particles into the cell.
Based on previous findings of Cav-1 involvement in the
late retroviral life cycle [13] we investigated the influence
Figure 4 M2 competition decreases influenza A/PR/8/34 titres in 
MDCK cells. Titres from infected MDCK cells transiently transfected 
with M2 fusion vectors or mock-Cells were infected with influenza A/
PR/8/34 virus 1 d after transfection, infectious titres were determined 1 
d later using plaque assays. The average of two independent experi-
ments is shown.
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of Cav-1 on human influenza A/PR/34 (H1N1) virus mul-
tiplication in inhibition experiments. It is crucial for our
investigation, that influenza virus entry does not occur
via caveolae, but can be mediated by chlatrin-dependent
endocytosis or another, not-defined pathway indepen-
dent of chlathrin-coated pits [32-34]. For example, it has
been shown, that a Cav-1 dominant-negative mutant
does not affect the entry of influenza virus [32]. The find-
ings are a prerequisite to exclude artifacts that may arise
from insufficient entry due to Cav-1 depletion in inhibi-
tion experiments. Applying different methods to impair
or inhibit Cav-1 function in MDCK, a knock-down pro-
cedure, a dominant-negative Cav-1 mutant as well as
competition experiments with M2 fusion proteins, we
could show that Cav-1 influences human influenza A
virus propagation. Inhibition methods have their limita-
tion, e.g., we noticed that Cav-1 RNAi-mediated knock-
down resulted in diminution of Cav-1 expression levels in
MDCK cells to 25% of Cav-1 wild-type level at the most.
Concomitantly, virus yield from these cells decreased 2-3
fold of virus levels observed from wild-type or RNAi-vec-
tor treated MCDK cells. Unfortunately, the effect of com-
plete absence of Cav-1 on human influenza A virus
production in MDCK cells could not be investigated, as
further reduction of Cav-1 levels cannot be achieved with
the retroviral RNAi system used [20]. This question may
be answered in a Cav-1 (-/-) MDCK cell line, which yet
has to be established.
D a t a  f r o m  k n o c k - d o w n  e x p e r i m e n t s  i n  M DC K  w e r e
supplemented by transfection of a dominant-negative
Cav-1 mutant as well as Cav-1 over-expression, which
decreased viral yields by 38-44%. The results are reminis-
cent of experiments of Nystrom et al. who observed
impairment of the insulin signalling pathway upon
expression of both, the dominant-negative Cav-1 mutant
and the over-expressed Cav-1 wt cDNA as well [21].
Finally, competition with M2 fusion proteins impaired
virus replication, too.
Taken together Cav-1 supports virus multiplication in
MDCK, but the cellular pathway directing this Cav-1
property is not known. It is conceivable, that the cellular
protein level of Cav-1 is important for the outcome, as it
has been suggested for Cav-1 involvement in the insulin
pathway [21].
Hints for the molecular basis of influenza virus/Cav-1
interaction may come from other viruses which co-opt
Cav-1. It is evident that individual stages in the various
viral life times are affected and different roles are allo-
cated to Cav-1 as well (Table 1). For example, the CBD
region in the HIV-1 gp41 transmembrane protein can
permeate membranes and is supposed to augment the
fusion step upon virus entry. Remarkably, respiratory
syncytial virus (RSV), induces Cav-1 phosphorylation,
which results in intracellular relocation of proteins dur-
ing the paramyxovirus life-cycle. In several cases, Cav-1
functions in positioning of viral proteins to intracellular
membranes (Rotavirus, SARS) or specialised regions of
the plasma membrane like lipid rafts (retrovirus MLV).
To understand the molecular basis of the Cav-1 contri-
bution to influenza A virus propagation we focussed on
Cav-1 interactions mediated by the caveolin-scaffolding
domain (CSD, aa 81-102) [25]. Database searches and
subsequent peptide pull-down assays in combination
with co-immunoprecipitation experiments suggested
binding of caveolin-1 to M2 presumably to a motif in the
M2 protein fitting the CBD consensus [26]. Strikingly, the
motif is shared in M2 of nearly all human influenza A
Figure 5 Specificity of Cav-1 binding to M2 of human Influenza A 
virus and the participation of cholesterol. A. Pull-down experi-
ments using biotinylated peptides representing the wt M2 CBD or a 
mutated sequence where aromatic residues in the CBD were changed 
to alanine. For Cav-1 detection after Western Blot a rabbit polyclonal 
antibody was used. B. Co-immunoprecipitation (Co-IP) experiments 
with pM2PR8-EGFP transfected or A/PR8 virus-infected cells. a. Lysates 
of pEP24c-transfected MDCK cells were processed for co-immumopre-
cipitation (polyclonal anti-Cav-1 antibody) followed by Western Blot 
detection of M2 (14C2). b. (Co-IP) of lysates of pM2PR8-EGFP transfect-
ed MDCK cells with or without cholesterol depletion by addition of 
methyl-β-cyclodextran (MβCD) (+) or mock-treatment (-) by rabbit 
polyclonal anti-Cav-1 antibody (Co-IP) and monoclonal mouse anti-
EGFP antibody (indirect M2 detection) were used. MDCK ID: Lysates 
from transfected cells processed for immunodetection only. c. Lysates 
of A/PR8 Virus infected cells were processed for immunodetection 
(MDCK ID) or co-immunoprecipiation (CoIP) after cholesterol deple-
tion with MBCD (+) or mock-treatment (-). Left panel: CoIP using rabbit 
anti-Cav-1 pAb and detection with anti-M2 antibody (14C2). Right pan-
el: Co-IP: mouse anti-EGFP mAb.Detection: rabbit anti-Cav-1 pAb.MD-
CK ID: lysates from infected MDCK cells processed for immuno-
detection.
A
Exp 1 Exp 2
M2    mut  no        M2  mut  no
B 1 234
(a)
1      2     3     4
M2
ID    CoIP  ID   CoIP
MDCK  CoIP        
ID +
NIH3T3 CoIP        
ID +
(b)
ID          + - ID          + -
M2-EGFP
MDCK CoIP MDCK CoIP
(c)
MDCK  CoIP        
ID          + -
M2
MDCK  CoIP        
ID          + -
Cav-1  
Cav-1  Sun et al. Virology Journal 2010, 7:108
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viruses. M2 functions within the viral life cycle as a
viroporin with proton channel activity that is crucial in
the entry phase [1] and as a maturation cofactor in virus
budding. The cytoplasmic tail is implicated in M1 bind-
ing and facilitates virus assembly and production [2-
4,35]. Furthermore, Schroeder et al. showed that avian
M2 is a cholesterol-binding protein [31]. Most avian
influenza A viruses contain two cholesterol recognition
motifs (CRAC I, CRAC II) in close vicinity to the trans-
membrane domain in the cytoplasmic region of M2
[31,36]. Thus, cholesterol-binding and palmitoylation in
combination with a short transmembrane region may
direct M2 to the raft periphery in membranes and may
promote clustering and merging of rafts which is then fol-
lowed by the pinching-off of avian viruses [31]. With this
model for avian influenza virus in mind it is conceivable
that the interaction of Cav-1 with M2 could direct the
protein into the vicinity of lipid rafts in human influenza
A virus infection. This view may be supported by differ-
ent observations: Firstly, we observed that the caveolin-1
binding domain is present in M2 of most human influ-
enza A virus strains and overlaps with a CRAC motif for
cholesterol binding. Such a high degree of evolutionary
conservation generally suggests a constant selective pres-
sure to preserve a specific function in the viral life cycle.
Secondly, Cav-1 itself binds cholesterol via a region in the
caveolin scaffolding domain [30]. Notably, to some
degree Cav-1 binding to M2 is sensitive to the cholesterol
depletion (this investigation). Preliminary results of
mutagenesis as well as localization experiments indicate a
certain role of the M2-CBD in M2 transport and localiza-
tion (unpublished observations). Taken together our
results demonstrate, that Cav-1 exerts an influence on
influenza A virus replication and data imply that the
binding of Cav-1 to the matrix protein M2 is involved.
However, which function or pathway in MDCK cells
actually is triggered via Cav-1 interaction with M2,
remains to be determined.
Conclusion
The appearance of the aggressive bird influenza (H5N1),
the 2009 outbreak of a pandemic influenza (H1N1) of
swine influenza origin, and the recent occurrence and
rapid dissemination of oseltamivir-resistant human influ-
enza strains are motors that have accelerated the search
for new antiviral targets and agents within the last time
[37-39]. The investigation of cellular mechanisms
involved in 'early' and 'late' viral processes and the identi-
fication of cellular actors provides a means to interfere
with viral strategies. With this respect, the observed Cav-
1/M2 interplay may represent a new, conserved target for
e.g. therapeutic intervention with circulating and newly
emerging strains of human influenza A virus. Thus, appli-
cation of high-throughput screening of compound librar-
ies will follow target identification and may result in a
new antiviral agent, as exemplified for a cellular target
involved in the late retroviral life cycle [40].
When this manuscript was in preparation Zhou et al.
reported binding of a cytoplasmic fragment of M2 from
human influenza to Cav-1 in an in vitro assay based on a
Cav-1 protein fragment expressed in E. coli and CBD-
dependent perinuclear co-localization upon expression in
CHO cells [41]. However, no experiments on the func-
tional importance of M2/Cav-1 were performed in this
investigation.
Materials and methods
Cells and viruses
MDCK Madin-Darby canine kidney (ATCC CCL-34) and
NIH 3T3 (ATCC CRL-1685) were maintained in Dul-
becco's modified Eagle's medium (DMEM) supplemented
with 10% fetal calf serum and 2 mM L-Glutamine at 37°C
in 5% CO2. Influenza A/Puerto RicoR/8/34 (H1N1,
Mount Sinai strain) virus was generously provided by
Stephan Ludwig (Virology, ZMBE, Muenster, Germany).
Chemicals
BCA protein assay kit (Pierce) Methyl-β-cyclodextrin
(MβCD, Sigma), octyl glucoside (Applichem) and other
chemicals were of the highest grade commercially avail-
able.
Plasmids
pCav-1 wt (myc-tagged canine Cav-1 cDNA in pCIS2)
and pCav-1 SD (point mutations F92A V94A in scaffold-
ing domain) are described elsewhere [21]. pM2PR8-
EGFP and pM2PR8-dsRED were constructed by PCR-
cloning of M2 (A/PR/8/34/(H1/N1) into BamHI/AgeI lin-
earized pEGFP-N1 and pDsRed-Express-N1 (Clontech),
respectively. M2 identity was verified by DNA sequenc-
ing. pEP24c (M2 cDNA) [29]. pRVH1-Puro-Cav-1 and
pRVH1-Puro [20] are described elsewhere.
Antibodies
Rabbit anti-caveolin 1 polyclonal antibody (pAb), mouse
anti-caveolin 1 monoclonal antibody (mAb) mouse anti-
EGFP mAb (JL-8) (all BD Transduction Laboratories)
mouse anti-Influenza A virus M2 monoclonal antibody
(14C2, ABR) were used according to the suggestions of
the supplier.
Infections
Infections with Influenza A/PR8/34 were performed in
the presence of trypsin (1-2 μg/ml) at a multiplicity of
infection (m.o.i) of 0.2-10 for 2 h at 37°C. Virus stocks
were prepared from supernatants of MDCK cell cultures
one day post infection (1 d.p.i.).Sun et al. Virology Journal 2010, 7:108
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Transfection
Plasmids were transfected into cells via Lipofectamine
2000 (Invitrogen or by calcium phosphate transfection
[42].
Lysis of cells
Lysates were prepared as described previously [13].
Plaque Assay
Influenza A/PR/8/34 titre was determined by plaque
assay on MDCK cells. PBS- washed MDCK were inocu-
lated with 500 μl of virus dilution for 1-2h at 37°C. Cells
were covered with 2 ml of MEM medium containing 1%
purified agar (Oxoid, England) and 1-2 μg/ml trypsin
(Sigma). After three days incubation at 37°C, plates were
stained with 0.03% neutral red staining to facilitate
plaque counting.
Pull-down experiments
20 μM biotinylated peptide encompassing either the con-
served CBD within human influenza M2 (Bio-β-Ala-
LDRLFFKCIYRFFKHGL-amid) or a mutant where the
CBD core motif is exchanged by alanine residues (Bio-β-
Ala-LDRLAFKCIYRFAKHGL-amid) were inoculated
with 50 μl NIH3T3 cell lysate (2 ml, T75 flask) for 90 min.
Complexes were immobilized using 10 μl streptavidin
coated paramagnetic microbeads and μ column (Milte-
nyi). Washed samples were eluted with 1× sample buffer
preheated at 95°C for 2 min and 15 μl out of 70 μl eluate
were separated by SDS PAGE, blotted to PVDF mem-
brane and probed with rabbit anti-caveolin-1 antibody.
Co-immunoprecipitation
Cell lysates were incubated with rabbit anti-caveolin-1
antibody (1:2000) or mouse anti-EGFP antibody (1:100)
at 4°C for 1 h, treated with 20-50 μl protein A- or G
microbeads (Miltenyi) at 4°C for 1 h, and processed as
described previously [13]. To deplete cholesterol, cell
lysates were treated with 10-20 mM MβCD at room tem-
perature for 1 h before co-immunoprecipitation.
SDS-PAGE and Western Blot
Protein concentrations were determined using the BCA
kit (Pierce). 5 μg total protein was separated on a vertical
12% separating gel. Subsequently, proteins were trans-
ferred to PVDF membranes using a Transblot™ Semi-dry
transfer cell (Bio-Rad). After blocking for 1 h (0.2% CA
blocking reagent, Applichem) immunostaining was per-
formed with primary antibody followed by 4 washing
steps (TBS 0,02% Tween 20) and addition of the second-
ary antibody at appropriate dilution. The blots were
developed with chemoluminescent substrate (Supersig-
nal Femto West, Supersignal Pico West, Pierce). The
band intensities were quantified using QuantityOne soft-
ware (Bio-Rad) and ImageJ.
Inhibition and competition experiments
Generation of Cav-1 knock-down MDCK using retrovirally 
mediated RNAi
The recombinant retroviral vectors were produced from
293T triple transfection of pCMV1MLVGP1, encoding
MLV  gagpol, pVSV-G, pRVH1-Puro-Cav-1 encoding a
shRNA for Cav-1 inhibition and a puromycin resistance
gene, as described [20]. For knock-down MDCK (60%-
80% confluency) were infected with the respective
shRNA retroviral vectors in the presence of 4 mg/ml
polybrene for 48 hours. Puromycin-resistant clones were
pooled and further analysed 10-27 days after infection.
Inhibition using a dominant-negative Cav-1 mutant
Plasmids pCav-1 wt or pCav-1 SD (Scaffolding domain
mutant) were transiently introduced into MDCK,
NIH3T3 or MEF 3T3 KO cells using lipofectamine 2000.
Competion with M2 fusion proteins
Plasmids pM2PR8_EGFP or pM2PR8DsRed were tran-
siently transfected into MDCK cells by lipofection. The
cells were infected with influenza A/PR/8 virus 1 day
after transfection. Virus titres were determined from
supernatants after additional 24 h of incubation at 37°C.
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